Kazia Therapeutics (KZIA) Accumulated Expenses (2017 - 2025)

Kazia Therapeutics (KZIA) has disclosed Accumulated Expenses for 6 consecutive years, with $249768.9 as the latest value for Q2 2025.

  • For the quarter ending Q2 2025, Accumulated Expenses rose 3.84% year-over-year to $249768.9, compared with a TTM value of $249768.9 through Jun 2025, up 3.84%, and an annual FY2025 reading of $252770.4, up 5.59% over the prior year.
  • Accumulated Expenses was $249768.9 for Q2 2025 at Kazia Therapeutics, up from $240543.9 in the prior quarter.
  • Across five years, Accumulated Expenses topped out at $461168.7 in Q2 2023 and bottomed at $145402.5 in Q2 2022.
  • Average Accumulated Expenses over 4 years is $274221.0, with a median of $245156.4 recorded in 2024.
  • The sharpest move saw Accumulated Expenses surged 217.17% in 2023, then crashed 47.84% in 2024.
  • Year by year, Accumulated Expenses stood at $145402.5 in 2022, then soared by 217.17% to $461168.7 in 2023, then plummeted by 47.84% to $240543.9 in 2024, then grew by 3.84% to $249768.9 in 2025.
  • Business Quant data shows Accumulated Expenses for KZIA at $249768.9 in Q2 2025, $240543.9 in Q2 2024, and $461168.7 in Q2 2023.